On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

HFpEF refers to when the heart is unable to pump enough blood to meet the body’s needs. Eli Lilly said the condition is linked to a “high burden” of symptoms and physical limitations that affect a ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

FDA approves Zepbound for sleep apnea treatment, marking first such approval FDA grants landmark approval for obesity drug ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...